Ebola virus disease (EVD) remains a serious public health threat in parts of Africa, with outbreaks causing high mortality and social disruption. Vaccination plays a crucial role in controlling these outbreaks and protecting those at highest risk. Two vaccines have gained approval for Ebola virus prevention: Ervebo, developed by Merck & Co., and the two-dose regimen of Zabdeno and Mvabea by Janssen Pharmaceutica.

The Nipah virus infection has emerged as a serious public health concern in India over the past two decades. This deadly virus has caused several outbreaks with high fatality rates, raising alarms among health authorities and communities alike. Understanding the origins, transmission, symptoms, and prevention of Nipah virus infection is crucial to controlling its spread and minimizing its impact. This article explores the key aspects of Nipah virus infection in India, highlig

Ebola virus disease (EVD) presents a significant challenge for healthcare providers, especially in regions where other infectious diseases with overlapping symptoms are common. Early symptoms of Ebola often mimic those of malaria, typhoid fever, and shigellosis, making accurate diagnosis difficult but critical. Misdiagnosis can delay appropriate treatment and increase the risk of transmission.